ReviewThe Korean journal of internal medicine2018
Novel treatments for inflammatory bowel disease.
Review in The Korean journal of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Novel Therapeutic Strategies and Biomarkers in the Management of Inflammatory Bowel Disease: A Narrative Review.Cureus · 2026Review
- Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease-Reports from a Romanian Center.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Intercellular interaction between FAP+ fibroblasts and CD150+ inflammatory monocytes mediates fibrostenosis in Crohn's disease.The Journal of clinical investigation · 2024Article
- Review
- APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease.Biomolecules · 2023Review
- Ileo-Anal Pouch Anastomosis and New Remedial Approaches for Ulcerative Colitis: A Review Article.Cureus · 2023Review
- Therapeutic Efficacy of Novel HDAC Inhibitors SPA3052 and SPA3074 against Intestinal Inflammation in a Murine Model of Colitis.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Vaccination strategies for Korean patients with inflammatory bowel disease.The Korean journal of internal medicine · 2022Review
- Inflammatory bowel disease in Korea: epidemiology and pathophysiology.The Korean journal of internal medicine · 2022Review
- Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.The Korean journal of internal medicine · 2022Review
- Observational
- IBD therapeutics: what is in the pipeline?Frontline gastroenterology · 2022Article
- Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer.Theranostics · 2021Article
- Review
- Organometallic Compounds and Metal Complexes in Current and Future Treatments of Inflammatory Bowel Disease and Colorectal Cancer-a Critical Review.Biomolecules · 2019Review
- Alternative Treatments for Minor GI Ailments.Innovations in pharmacy · 2019Review
- Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease.Chinese medicine · 2019Review
- Impact of Modern Drug Therapy on Surgery: Ulcerative Colitis.Visceral medicine · 2018Review
- Drug Lag for Inflammatory Bowel Disease Treatments in the East and West.Inflammatory intestinal diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased understanding of the immunopathology of inflammatory bowel disease (IBD) has led to the development of targeted therapies and has unlocked a new era in IBD treatment. The development of treatment options aimed at a variety of pathological mechanisms offers new hope for customized therapies. Beyond anti-tumor necrosis factor agents, selective lymphocyte trafficking inhibitors have been proposed as potent drugs for IBD. Among these, vedolizumab has recently been approved for both Crohn's disease and ulcerative colitis. Numerous other agents for IBD treatment are currently under investigation, including Janus kinase inhibitors, anti-mucosal vascular addressin cell adhesion molecule-1 agents, an anti-SMAD7 antisense oligonucleotide, an anti-interleukin-12/23 monoclonal antibody, and a sphingosine-1-phosphate receptor-1 selective agonist. These agents will likely expand the treatment options available for the management of IBD patients in the future. In this review, we discuss the efficacy and safety of novel agents currently under investigation in IBD clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.